Most patients start noticing a reduction in appetite and experience a sense of fullness after meals within the first few weeks
GLP-1 drugs enhance this response, which can be particularly helpful among people with type 2 diabetes, who may have a reduced natural GLP-1 response
The fourth is body composition trend - not just scale weight
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
They with an NSAID avoided the increase in gut permeability seen in the placebo group
These products are not intended for human consumption and must not be used for the diagnosis, treatment, cure, or prevention of any disease or medical condition